DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0306027 A1 Worcel Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0306027 A1 Worcel Et Al US 20090306027A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0306027 A1 Worcel et al. (43) Pub. Date: Dec. 10, 2009 (54) GENETIC RISK ASSESSMENT IN HEART (86). PCT No.: PCT/US2O07/OO8426 FAILURE IMPACT OF THE GENETIC VARATION OF G-PROTEIN BETA3 S371 (c)(1), SUBUNIT POLYMORPHISM (2), (4) Date: Jun. 25, 2009 Related U.S. Application Data (75) Inventors: Manuel Worcel, Boston, MA (US); (60) Provisional application No. 60/790,555, filed on Apr. Michael Sabolinski, Franklin, MA 10, 2006. (US); Sang W. Tam, Dover, MA (US); Dennis M. McNamara, Publication Classification Venetia, PA (US) (51) Int. Cl. A6II 3/56 (2006.01) Correspondence Address: A6II 3/34 (2006.01) WILMERHALEANTROMED A63L/502 (2006.01) 1875 PENNSYLVANIAAVE, NW (52) U.S. Cl. .......................... 514/171; 514/470; 514/248 WASHINGTON, DC 20006 (US) (57) ABSTRACT The invention provides methods for treating various indica (73) Assignees: NitoMed, Inc., Lexington, MA tions and diseases in a patient in need thereof, wherein the (US); Unversity of Pittsburgh of patient has a C825T polymorphism in the G protein beta3 the Commonwealth System of the Subunit (GNB3), comprising administering to the patient (i) Higher Education, Pittsburgh, PA at least one antioxidant compound or a pharmaceutically (US) acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the (21) Appl. No.: 12/296,630 antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing com (22) PCT Filed: Apr. 4, 2007 pound is isosorbide dinitrate and/or isosorbide mononitrate. Patent Application Publication Dec. 10, 2009 Sheet 1 of 4 US 2009/0306027 A1 Figure 1 SO 50 - 40 32227 genotype so20 k. s 2 TTTC og 2 -4tal-rzazar Blacks Blacks Whites (A-HeFT) (GRACE) (GRACE) Patent Application Publication Dec. 10, 2009 Sheet 2 of 4 US 2009/0306027 A1 Figure 2 I-H = fixed dose combination of isosorbide dinitrate and hydraiazine hydrochloride GNB3TT Subjects: Event-free Survival, I-H vs. Placebo 100 2s :O e i 70 so ---- l ir Place 50 P = 0.047 AO O 10 200 300 400 500 Patent Application Publication Dec. 10, 2009 Sheet 3 of 4 US 2009/0306027 A1 Figure 3 A 0.8 D Placebo ISDN-HYD -O.2 GNB3 TT only GNB3 TC+CC p=0.016, n=184 p=0.871, n=166 Patent Application Publication Dec. 10, 2009 Sheet 4 of 4 US 2009/0306027 A1 Figure 3 B O.8 Placebo ISDN-HYD GNB3 TT only GNB3 TC+CC "p=0.039, n=184 p=0.563, n=166 US 2009/03 06027 A1 Dec. 10, 2009 GENETIC RISKASSESSMENT IN HEART from oxidative stress; (p) treating endothelial dysfunctions; FAILURE IMPACT OF THE GENETIC (q) treating diseases caused by endothelial dysfunctions; (r) VARATION OF G-PROTEIN BETA3 treating cardiovascular diseases; in a patient in need thereof, SUBUNIT POLYMORPHISM wherein the patient has a a C825T polymorphism in the G protein beta3 subunit, comprising administering to the patient RELATED APPLICATIONS (i) at least one antioxidant compound or pharmaceutically 0001. This application claims priority under 35 USC S119 acceptable salt thereof; (ii) at least one nitric oxide enhancing to U.S. Application No. 60/790,555 filed Apr. 10, 2006; the compound; and (iii) optionally at least one compound disclosure of which is incorporated by reference herein in its selected from the group consisting of an angiotensin convert entirety. ing enzyme inhibitor, a B-adrenergic antagonist, an angio tensin II antagonist, an aldosterone antagonist, a cardiac gly FIELD OF THE INVENTION coside and a diuretic compound or a combination of two or 0002 The invention provides methods for (a) reducing more thereof. In another embodiment the patient has at least mortality associated with heart failure; (b) improving oxygen one polymorphism in an endothelial nitric oxide synthase consumption; (c) treating heart failure; (d) treating hyperten (NOS3) gene and/or at least one polymorphism in a beta 1 sion; (e) improving the quality of life in a heart failure patient; adrenergic receptor gene and/or at least one polymorphism in (f) inhibiting left ventricular remodeling; (g) reducing hospi an aldosterone synthase CYP11B2 gene. In another embodi talizations related to heart failure; (h) improving exercise ment, the patient is categorized as New York Heart Associa tolerance; () increasing left Ventricular ejection fraction; (k) tion heart failure functional classification I, II, III or IV. In yet decreasing levels of B-type natriuretic protein; (1) treating another embodiment, the patient is categorized as New York renovascular diseases; (m) treating end-stage renal diseases; Heart Association heart failure functional classification II, III (n) reducing cardiomegaly; (O) treating diseases resulting or IV. In yet another embodiment the patient is a blackpatient. from oxidative stress; (p) treating endothelial dysfunctions; In one embodiment the antioxidant is a hydralazine com (q) treating diseases caused by endothelial dysfunctions; or pound or a pharmaceutically acceptable salt thereof and the (r) treating cardiovascular diseases; in a patient in need nitric oxide enhancing compound is isosorbide dinitrate and/ thereof, wherein the patient has a C825T polymorphism in the or isosorbide mononitrate. The antioxidants, nitric oxide G proteinbeta3 subunit (GNB3), comprising administering to enhancing compounds and/or additional compounds can be the patient (i) at least one antioxidant compound or a phar administered separately or as components of the same com maceutically acceptable salt thereof; (ii) at least one nitric position in one or more pharmaceutically acceptable carriers. oxide enhancing compound; and (iii) optionally the best cur 0006. The invention provides methods for (a) reducing rent therapy for the treatment of cardiovascular diseases. In mortality associated with heart failure; (b) improving oxygen one embodiment the antioxidant is a hydralazine compound consumption; (c) treating heart failure; (d) treating hyperten or a pharmaceutically acceptable salt thereof and the nitric sion; (e) improving the quality of life in a heart failure patient; oxide enhancing compound is isosorbide dinitrate and/or (f) inhibiting left ventricular remodeling; (g) reducing hospi isosorbide mononitrate. talizations related to heart failure: (h) improving exercise tolerance; () increasing left Ventricular ejection fraction; (k) BACKGROUND OF THE INVENTION decreasing levels of B-type natriuretic protein; (1) treating renovascular diseases; (m) treating end-stage renal diseases; 0003 Genetic background appears to influence outcomes (n) reducing cardiomegaly; (O) treating diseases resulting for patients with congestive heart failure. The G protein beta from oxidative stress; (p) treating endothelial dysfunctions; 3-subunit (GNB3) plays an important role in alpha adrenergic (q) treating diseases caused by endothelial dysfunctions; (r) signaling. A common polymorphism (C825T) exists in exon treating cardiovascular diseases; in a patient in need thereof, 10 (i.e. G-protein beta3 subunit (GNB3) C825T polymor wherein the patient has a C825T polymorphism in the G phism). The T haplotype is linked to a splicing variant of protein beta3 subunit, comprising administering to the patient GNB3 which results in enhanced alpha adrenergic tone and is (i) at least one antioxidant compound or pharmaceutically more prevalent in African Americans than in white cohorts. acceptable salt thereof; (ii) at least one nitric oxide enhancing The Thaplotype has also been linked to the risk of hyperten compound; (iii) analdosterone antagonist; and (iv) optionally Sion, and may affect the response to angiotensin converting at least one compound selected from the group consisting of enzyme inhibitors. an angiotensin converting enzyme inhibitor, a B-adrenergic 0004. There is a need in the art for the determination of a antagonist, an angiotensin II antagonist, a cardiac glycoside patient's genetic variation and for the treatment of heart fail and a diuretic compound or a combination of two or more le. thereof. In another embodiment the patient has at least one polymorphism in an endothelial nitric oxide synthase (NOS3) SUMMARY OF THE INVENTION gene and/or at least one polymorphism in a beta 1 adrenergic 0005. The invention provides methods for (a) reducing receptor gene and/or at least one polymorphism in an aldos mortality associated with heart failure; (b) improving oxygen terone synthase CYP11B2 gene. In one embodiment the anti consumption; (c) treating heart failure; (d) treating hyperten oxidant is a hydralazine compound or a pharmaceutically sion; (e) improving the quality of life in a heart failure patient; acceptable salt thereof and the nitric oxide enhancing com (f) inhibiting left ventricular remodeling; (g) reducing hospi pound is isosorbide dinitrate and/or isosorbide mononitrate. talizations related to heart failure; (h) improving exercise In these embodiments of the invention, the methods can tolerance; () increasing left Ventricular ejection fraction; (k) involve (i) administering the hydralazine compound or a decreasing levels of B-type natriuretic protein; (1) treating pharmaceutically acceptable salt thereof, and at least one of renovascular diseases; (m) treating end-stage renal diseases; isosorbide dinitrate and/or isosorbide mononitrate, and an (n) reducing cardiomegaly; (O) treating diseases resulting aldosterone antagonist or (ii) administering the hydralazine US 2009/03 06027 A1 Dec. 10, 2009 compound
Load more

Recommended publications
  • Use of Gasotransmitters for the Controlled Release of Polymer
    Journal of Controlled Release 279 (2018) 157–170 Contents lists available at ScienceDirect Journal of Controlled Release journal homepage: www.elsevier.com/locate/jconrel Review article Use of gasotransmitters for the controlled release of polymer-based nitric T oxide carriers in medical applications ⁎ ⁎⁎ Chungmo Yanga,1, Soohyun Jeonga,1, Seul Kub, Kangwon Leea,c, , Min Hee Parka, a Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Republic of Korea b School of Medicine, Stanford University, 291 Campus Drive, Stanford, CA 94305, USA c Advanced Institutes of Convergence Technology, Gyeonggi-do 16229, Republic of Korea ARTICLE INFO ABSTRACT Keywords: Nitric Oxide (NO) is a small molecule gasotransmitter synthesized by nitric oxide synthase in almost all types of Nitric oxide mammalian cells. NO is synthesized by NO synthase by conversion of L-arginine to L-citrulline in the human Polymeric carrier body. NO then stimulates soluble guanylate cyclase, from which various physiological functions are mediated in fi Hydrogen sul de a concentration-dependent manner. High concentrations of NO induce apoptosis or antibacterial responses Carbon monoxide whereas low NO circulation leads to angiogenesis. The bidirectional effect of NO has attracted considerable Crosstalk of gasotransmitters attention, and efforts to deliver NO in a controlled manner, especially through polymeric carriers, has been the Stimuli-responsive topic of much research. This naturally produced signaling molecule has stood out as a potentially more potent therapeutic agent compared to exogenously synthesized drugs. In this review, we will focus on past efforts of using the controlled release of NO via polymer-based materials to derive specific therapeutic results.
    [Show full text]
  • Comparison of the Antiischaemic and Antianginal Effects of Nicorandil and Amlodipine in Patients with Symptomatic Stable Angina Pectoris: the SWAN Study
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 1999; 2 (2), 213-217 Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study The SWAN Study Group Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL The SWAN study J Clin Basic Cardiol 1999; 2: 213 Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study The SWAN Study Group1 This multicentre, double-blind, randomised study compared the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris. Nicorandil is a new coronary and balanced peripheral vasodilating agent that operates through two mechanisms of action: activation of ATP-dependent K-channels and stimulation of guanylate cyclase. A total of 121 patients with symptomatic stable angina pectoris were randomised to receive nicorandil 10 mg twice daily (bd) or amlodipine 5 mg once daily (od) for 8 weeks (optional dosage increase after 2-4 weeks to 20 mg bd and 10 mg od, respec- tively). Symptom-limited exercise tolerance tests were performed at baseline, and after 2 and 8 weeks treatment, respectively. In addition, the number of anginal attacks, nitroglycerin (NTG) usage, blood pressure (BP), heart rate (HR) and adverse events were recorded, and a subjective assessment of quality of life performed.
    [Show full text]
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • Current Status of Local Penile Therapy
    International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Current status of local penile therapy F Montorsi1*, A Salonia1, M Zanoni1, P Pompa1, A Cestari1, G Guazzoni1, L Barbieri1 and P Rigatti1 1Department of Urology, University Vita e Salute – San Raffaele, Milan, Italy Guidelines for management of patients with erectile dysfunction indicate that intraurethral and intracavernosal injection therapies represent the second-line treatment available. Efficacy of intracavernosal injections seems superior to that of the intraurethral delivery of drugs, and this may explain the current larger diffusion of the former modality. Safety of these two therapeutic options is well established; however, the attrition rate with these approaches is significant and most patients eventually drop out of treatment. Newer agents with better efficacy-safety profiles and using user-friendly devices for drug administration may potentially increase the long-term satisfaction rate achieved with these therapies. Topical therapy has the potential to become a first- line treatment for erectile dysfunction because it acts locally and is easy to use. At this time, however, the crossing of the barrier caused by the penile skin and tunica albuginea has limited the efficacy of the drugs used. International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81. DOI: 10.1038= sj=ijir=3900808 Keywords: erectile dysfunction; local penile therapy; topical therapy; alprostadil Introduction second patient category might be represented by those requesting a fast response, which cannot be obtained by sildenafil; however, sublingual apomor- Management of patients with erectile dysfunction phine is characterized by a fast onset of action and has been recently grouped into three different may represent an effective solution for these 1 levels.
    [Show full text]
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • Alphabetical Listing by Therapeutic Category GOODFELLOW AFB ROSS CLINIC FORMULARY
    GOODFELLOW AFB ROSS CLINIC FORMULARY Alphabetical Listing by Therapeutic Category This document is current as of October 8, 2020. The availability of formulary items is subject to change. ACARBOSE Acarbose ALPRAZolam Outpatient Dosage Forms Outpatient Formulary Brands Available Xanax Tablet, Oral: Outpatient Dosage Forms Generic: 25 mg, 50 mg, 100 mg Tablet, Oral: Xanax: 0.5 mg, 1 mg [scored] Acetaminophen Generic: 0.5 mg, 1 mg Outpatient Formulary Brands Available Mapap Children's [OTC]; Mapap [OTC] Aluminum Chloride Hexahydrate Outpatient Dosage Forms Outpatient Formulary Brands Available Drysol Suspension, Oral: Outpatient Dosage Forms Mapap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains propylene Solution, External: glycol, sodium benzoate; cherry flavor] Drysol: 20% (60 mL) Tablet, Oral: Mapap: 325 mg Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone Generic: 325 mg Outpatient Dosage Forms Liquid, Oral: Acetaminophen and Codeine Generic: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and Outpatient Dosage Forms simethicone 20 mg per 5 mL (360 mL) Solution, Oral [C-V]: Generic: Acetaminophen 120 mg and codeine phosphate 12 mg per 5 mL Amantadine (118 mL) [BCF] Outpatient Dosage Forms Tablet, Oral [C-III]: Capsule, Oral, as hydrochloride: Generic: Acetaminophen 300 mg and codeine phosphate 30 mg [BCF] Generic: 100 mg [BCF] AcetaZOLAMIDE Amiodarone Outpatient Dosage Forms Outpatient Dosage Forms Tablet, Oral: Tablet, Oral, as hydrochloride: Generic: 250 mg Generic: 200 mg [BCF] Acetic Acid, Propylene Glycol Diacetate,
    [Show full text]
  • Drug Class Review Antianginal Agents
    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
    [Show full text]
  • Enantioselective Synthesis Of
    ENANTIOSELECTIVE SYNTHESIS OF PHORACANTHOLIDE I, MEXILETINE, ENCIPRAZINE, ESMOLOL, ATENOLOL, XIBENOLOL VIA α- AMINOXYLATION OF ALDEHYDE AND APPLICATION OF RECYCLABLE CATALYSIS IN ORGANIC TRANSFORMATION A THESIS SUBMITTED TO THE UNIVERSITY OF PUNE FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN CHEMISTRY BY MOHSINKHAN YASEENKHAN PATHAN DR. SHAFEEK A. R. MULLA (RESEARCH GUIDE) CHEMICAL ENGINEERING AND PROCESS DEVELOPMENT DIVISION, NATIONAL CHEMICAL LABORATORY, PUNE- 411008, INDIA APRIL 2014 Mr. Yaseenkhan Sajjankhan Pathan Mrs. Farjana Yaseenkhan Pathan NATIONAL CHEMICAL LABORATORY DR. SHAFEEK A. R. MULLA Senior Scientist Ph.D. FMASc. AvH Fellow (Germany), JSPS Fellow (Japan) Chemical Engineering & Process Development Division Dr. Homi Bhabha Road, Pune – 411 008, India Tel.:+91-20-25902316, Fax:+91-20-25902676 E-mail : [email protected]/[email protected] CERTIFICATE Certified that the work incorporated in the thesis entitled “Enantioselective Synthesis of Phoracantholide I, Mexiletine, Enciprazine, Esmolol, Atenolol, Xibenolol via α- Aminoxylation of Aldehyde and Application of Recyclable Catalysis in Organic Transformation” was carried out by the candidate under my supervision. Such material as had been obtained from other sources has been duly acknowledged in the thesis. April 2014 (Dr. Shafeek. A. R. Mulla) Pune Research Guide NATIONAL CHEMICAL LABORATORY DECLARATION I here by declare that the thesis entitled “Enantioselective Synthesis of Phoracantholide I, Mexiletine, Enciprazine, Esmolol, Atenolol, Xibenolol via α-Aminoxylation of Aldehyde and Application of Recyclable Catalysis in Organic Transformation” submitted for the degree of Doctor of Philosophy in Chemistry to the University of Pune, has not been submitted by me to any other university or institution. This work was carried out at the National Chemical Laboratory, Pune, India.
    [Show full text]
  • Diuretic Cocktail"
    Clinical evaluation of a "diuretic cocktail" LAWRENCE J. GALLA, A.B., D.O., and WIL- acetazoleamide depressing hydration of carbon LIAM BALDWIN, JR., D.O., F.A.C.0.1., York, dioxide, exchange resins drawing salt from food Pennsylvania in the intestinal tract, or water diuresis. Therefore, diuretic therapy should be planned to permit daily salt and water balance. The treatment should take into account the particular type of fluid or electro- The characteristics of an ideal diuretic can be lyte to be removed, the need for speed in its re- easily enumerated; it should be effective without moval, and the setting in which it will be done. producing electrolyte disturbance, nephrotoxicity, Oral diuretics, for example, are desirable; however, sensitivity, refractoriness, or cardiac toxicity. How- they are often not powerful enough for acute or ever, in practice, a compound encompassing these emergency problems, or they may irritate the pa- properties remains to be found. Furthermore, be- tient's stomach. It may be said that oral diuretics cause of the many factors involved in the patho- are useful in cases where a modest diuretic action logic states that result in abnormal water retention, is satisfactory. Other clinical situations are met by a universal diuretic—that is, one that will work in other means. every situation—has yet to to be made available. Diet is rather important. Patients with edema In recent years a number of new diuretic drugs will probably have to accept a low-salt diet sooner utilizing various physiologic principles have ap- or later; the sooner they start, the sooner better peared.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,641,839 B1 Geoghegan Et Al
    USOO6641839B1 (12) United States Patent (10) Patent No.: US 6,641,839 B1 Geoghegan et al. (45) Date of Patent: Nov. 4, 2003 (54) PHARMACEUTICAL FORMULATIONS FOR JP 59 84.820 5/1984 PREVENTING DRUG TOLERANCE JP 62126127 * 6/1987 (75) Inventors: Edward James Geoghegan, Athlone OTHER PUBLICATIONS (IE); Seamus Mulligan, Athlone (IE); “Isosorbide-5-Nitrate Sustained-release pellets-an Mary Margaret Foynes, Athlone (IE) example of computer Supported drug development', Zerbe et al., Pharmacuetical Resarch 1985, No. 1, Jan., pp. 30–36. (73) Assignee: Athpharma Limited, Roscommon (IE) “Glyceryl trinitrate (nitroglycerine) and the Organic nitrates choosing the method of administration”, J. Abrahms, Drugs (*) Notice: Subject to any disclaimer, the term of this 34; 391-403 (1987). patent is extended or adjusted under 35 “Dose Dependence of Tolerance during treatment with U.S.C. 154(b) by 407 days. mono-nitrates', M. Tauchert et al., Z. Cardiol. 72, Suppl. 3, 218–228 (1983). (21) Appl. No.: 08/797,318 “Tolerance Development during isosorbide dinitrate treat ment: Can it be circumvented?”, W. Rudolf et al., Z. Cardiol. (22) Filed: Feb. 7, 1997 72, Supple. 3, 195-198 (1983). Related U.S. Application Data “Anti-ischemic effects of 80mg tablet of isosorbide dinitrate in Sustained-release form before and after two weeks treat (63) Continuation of application No. 08/419,520, filed on Apr. ment with 80mg once daily or twice daily', S.Silver et al., 10, 1995, which is a continuation of application No. 08/320, Z.Cardiol. 72, Suppl. 3, 211-217 (1983). 599, filed on Oct. 11, 1994, which is a continuation of application No.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]